# US 2025/0090723 A1 · Tissue graft and processing methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0090723 A1
- Document ID: US20250090723A1
- Status: Published application
- Kind: A1
- Application number: 18/729,369
- Filed: 2023-01-19
- Published: 2025-03-20
- Earliest claimed: 2022-01-19
- Applicants: Restoration Biologics LLC
- Inventors: Suzanne M. TABBAA; William D. BUGBEE; Farshid GUILAK
- Web page: https://patentgrep.com/patent/US20250090723A1

## CPC

- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61F 2/28: Bones
- A61F 2/30756: {Cartilage endoprostheses (A61F2/3603 takes precedence)}
- A61F 2/4644: {Preparation of bone graft, bone plugs or bone dowels, e.g. grinding or milling bone material (bone material A61F2/28; disintegrating or milling devices B02C)}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- A61F 2002/2835: {Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material}
- A61F 2002/2839: {Bone plugs or bone graft dowels}
- A61F 2002/30762: {Means for culturing cartilage}
- A61F 2002/30764: {Cartilage harvest sites}
- A61F 2002/30766: {Scaffolds for cartilage ingrowth and regeneration}
- A61F 2002/4646: {Devices for cleaning bone graft}
- A61F 2002/4648: {Means for culturing bone graft}
- A61F 2002/4649: {Bone graft or bone dowel harvest sites}
- A61L 2400/18: Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein is a modified tissue graft (120, 200, 300, 500, 630) with improved properties for tissue integration and regeneration. The tissue graft (120, 200, 300, 500, 630) has biological properties that are enhanced by removing lipids (615) and other contaminants (e.g., blood components, micro-organisms) using enzymes, enzyme aggregates, or immobilized enzymes. This application describes the process (10) for removing bio-contaminants while maintaining optimal biological properties.

## Claims

### Claim 1

A tissue graft comprising:
tissue with enhanced biological properties and
an amount of contaminants, wherein the contaminants include: marrow contents, blood vessels, neural tissue, adipocytes, allogeneic cells, immunogenic cells, blood cells, lipids, blood components, proteins, microorganisms or viral mRNA, and wherein the amount of contaminants is reduced by 50%, when compared to normal tissue, with enzymes, enzyme aggregates, or immobilized enzymes.

### Claim 2 (depends on 1)

The tissue graft of claim 1, wherein the tissue includes:
bone or osteochondral tissue or soft tissues including a least one of meniscus, cartilage, ligament, tendon, bone, pericardium, intervertebral disc, nervous tissue, blood vessels, heart valves, muscle, dermal tissue, and organs.

### Claim 3 (depends on 1)

The tissue graft of claim 1 wherein the tissue includes lipids and contaminants below a clinically significant level, with a reduction of at least 70% when compared to normal tissue.

### Claim 4 (depends on 1)

The tissue graft of claim 1 wherein the tissue includes channels, grooves, or a modified surface to enhance penetration of an agent.

### Claim 5 (depends on 1)

The tissue graft of claim 1 wherein the tissue further includes a bony portion including partially demineralized tissue.

### Claim 6 (depends on 1)

The tissue graft of claim 1 wherein the enzymes include a non-specific lipase or 1,3-specific lipase with activity from 0-40° C.

### Claim 7 (depends on 6)

The tissue graft of claim 6, wherein a minimum dose of 0.01% of a lipid substrate in the graft is used to treat the graft.

### Claim 8 (depends on 1)

The tissue graft of claim 1 wherein the enzymes include a combination of specific enzyme types including lipases, collagenases, phospholipases, proteases, proteinases, matrix metalloproteinases, phytases, colipase, nucleases, amylases, or esterases.

### Claim 9

A method for removing contaminants from a tissue graft comprising:
obtaining a tissue graft contaminated with one or more of the following contaminates: marrow contents, blood vessels, neural tissue, adipocytes, allogeneic cells, immunogenic cells, blood cells, lipids, blood components, proteins, microorganisms and viral mRNA, and
removing the contaminants with a combination of enzymes, enzyme aggregates, immobilized enzymes, CO2, or cryoablation.

### Claim 10 (depends on 9)

The method of claim 9 comprising applying enzyme aggregates to remove the contaminants.

### Claim 11 (depends on 10)

The method of claim 10, comprising applying enzyme aggregates, wherein the enzyme aggregates are cross-linked with and without magnetic particles to facilitate controlled removal of contaminants.

### Claim 12 (depends on 10)

The method of claim 10, wherein the tissue graft is a biphasic osteochondral tissue graft, and the method further comprises applying enzyme aggregates, wherein the enzyme aggregates vary in a size range between 6 nm-50 μm and contain 1 to 50,000 enzymes per aggregate.

### Claim 13 (depends on 10)

The method of claim 10, comprising applying enzyme combinations or aggregates, wherein enzyme combinations or aggregates contain one more multiple types of enzymes including lipases, collagenases, phospholipases, proteases, proteinases, phytases, amylases, esterases, cathepsins, matrix metalloproteinases, papain, trypsin, pepsin, amylase, nucleases, colipases, or combinations thereof.

### Claim 14 (depends on 9)

The method of claim 9, further comprising:
forming tissue modifications including channels, grooves, or perforations.

### Claim 15 (depends on 14)

The method of claim 14, wherein the forming the tissue modifications includes drilling or cutting with a water cutter, drill, or laser.

### Claim 16 (depends on 9)

The method of claim 9 comprising cryoablation with liquid gas or biocompatible cryogens.

### Claim 17 (depends on 9)

The method of claim 9, further comprising:
removing lipid and other contaminants from the tissue using CO2.

### Claim 18 (depends on 9)

The method of claim 9, further comprising employing vacuum extraction with any combination of enzymes, CO2, or cryoablation.
